Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Outlook Therapeutics (OTLK) Interest Expenses (2016 - 2020)

Outlook Therapeutics (OTLK) has disclosed Interest Expenses for 6 consecutive years, with $443624.0 as the latest value for Q2 2020.

  • Quarterly Interest Expenses fell 58.99% to $443624.0 in Q2 2020 from the year-ago period, while the trailing twelve-month figure was $443624.0 through Jun 2025, changed N/A year-over-year, with the annual reading at $3.2 million for FY2024, 24.72% up from the prior year.
  • Interest Expenses for Q2 2020 was $443624.0 at Outlook Therapeutics, down from $696151.0 in the prior quarter.
  • The five-year high for Interest Expenses was $2.1 million in Q3 2017, with the low at -$788893.0 in Q3 2018.
  • Average Interest Expenses over 5 years is $793335.1, with a median of $707017.0 recorded in 2017.
  • The sharpest move saw Interest Expenses surged 482.94% in 2017, then crashed 136.74% in 2018.
  • Over 5 years, Interest Expenses stood at $489145.0 in 2016, then skyrocketed by 46.76% to $717883.0 in 2017, then surged by 56.13% to $1.1 million in 2018, then plummeted by 46.68% to $597665.0 in 2019, then dropped by 25.77% to $443624.0 in 2020.
  • According to Business Quant data, Interest Expenses over the past three periods came in at $443624.0, $696151.0, and $597665.0 for Q2 2020, Q1 2020, and Q4 2019 respectively.